Researchers from Harvard Medical School found that they can tweak a gene and turn a patient’s own pancreatic cells into insulin-producing cells.
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.
Researchers at Johns Hopkins Medicine have uncovered a critical biological mechanism that helps explain how inflammation is triggered and sustained in a wide range of diseases—highlighting a promising avenue for future therapeutic development.
BOSTON, Sept. 4, 2026 /PRNewswire/ — HoneyNaps, specializing in AI-powered sleep medical devices, has developed a next-generation wireless polysomnography system that combines patch-based skin sensors with artificial intelligence-driven analysis.
StethO Sense, a new Withings+ service powered by eMurmur® and StethoMe, brings on-demand AI-powered heart sound analysis and breathing pattern insights to BeamO users, allowing families to track changes in heart sounds and breathing patterns early from home.
Medtronic (NYSE: MDT) has secured a CE mark for its Endurant stent graft, removing a treatment warning related to its use in ruptured abdominal aortic aneurysms (AAA).
Globus Medical (NYSE: GMED) has secured a CE mark for its Excelsius3D intelligent 3-in-1 imaging system for spine and cranial procedures.
A lab-grown micro bladder may explain why urinary tract infections (UTIs) return so frequently, according to a study led by researchers at UCL, the University of Oxford and the University of Leicester.
Atherosclerosis predominantly affects regions of the arteries that bend or branch, creating disturbances in blood flow dynamics that activate cells’ inflammatory pathways and eventually lead to plaque buildup.
A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing LDL (“bad”) cholesterol and triglycerides in people with medication-resistant lipid disorders through one year of follow-up across all doses.